Acadia Pharmaceuticals | ACAD - Market Capitalization


Acadia Pharmaceuticals reported $4.35B in Market Capitalization this February of 2026, considering the latest stock price and the number of outstanding shares.





Market Capitalization Change Date
Acadia Pharmaceuticals USD 3.6B 10M Sep/2025
ALKERMES USD 4.95B 235M Sep/2025
Alnylam Pharmaceuticals USD 59.77B 17.25B Sep/2025
Biogen USD 20.54B 2.13B Sep/2025
BioMarin Pharmaceutical USD 10.4B 142M Sep/2025
Bristol-Myers Squibb USD 91.8B 2.4B Sep/2025
Corcept Therapeutics USD 8.76B 977M Sep/2025
Cytokinetics USD 6.58B 2.63B Sep/2025
Eisai JPY 1.45T 280.95B Sep/2025
Eli Lilly USD 722.15B 16.64B Sep/2025
Incyte USD 16.56B 3.38B Sep/2025
J&J USD 500.24B 67.44B Dec/2025
Moderna USD 10.09B 581M Sep/2025
Neurocrine Biosciences USD 13.92B 1.48B Sep/2025
Pfizer USD 147.57B 12.48B Feb/2026
Prothena USD 473M 52M Feb/2026
PTC Therapeutics USD 4.88B 1B Sep/2025
Sarepta Therapeutics USD 2.02B 336M Sep/2025
Ultragenyx Pharmaceutical USD 2.9B 539M Sep/2025
Vertex Pharmaceuticals USD 100.41B 13.91B Sep/2025